大唐药业(836433) - 2022 Q1 - 季度财报

Financial Performance - Operating revenue for Q1 2022 was CNY 28,484,733.38, representing a decline of 25.62% year-on-year[16] - Net profit attributable to shareholders for Q1 2022 was CNY 5,560,706.73, down 45.09% compared to the same period last year[16] - The net profit after deducting non-recurring gains and losses decreased by 59.02% year-on-year, amounting to CNY 3,713,600.84[16] - Basic earnings per share for Q1 2022 were CNY 0.04, a decrease of 42.86% from CNY 0.07 in Q1 2021[16] - Total operating revenue for Q1 2022 was CNY 28,484,733.38, a decrease of 25.6% compared to CNY 38,297,693.93 in Q1 2021[38] - The net profit for Q1 2022 was CNY 5,560,706.73, down 45.0% from CNY 10,126,885.66 in Q1 2021[40] - The total profit for Q1 2022 was CNY 6,388,303.95, a decline of 47.4% from CNY 12,138,509.83 in Q1 2021[40] - The total comprehensive income for Q1 2022 was CNY 5,560,706.73, a decrease of 45.0% compared to CNY 10,126,885.66 in Q1 2021[40] Cash Flow - The company's cash flow from operating activities was CNY 66,622,261.16, compared to a negative cash flow of CNY 13,814,864.56 in the previous year[16] - The cash inflow from operating activities for Q1 2022 was ¥104,649,776.57, a significant increase from ¥45,079,825.11 in Q1 2021, representing a growth of approximately 132.5%[45] - The net cash flow from operating activities for Q1 2022 was ¥66,622,261.16, compared to a negative cash flow of ¥13,814,864.56 in Q1 2021, indicating a turnaround in operational performance[45] - The total cash inflow from investment activities in Q1 2022 was ¥274,865,172.10, down from ¥382,313,126.27 in Q1 2021, reflecting a decrease of about 28.1%[47] - The net cash flow from investment activities for Q1 2022 was ¥166,654,874.13, a recovery from a negative cash flow of ¥4,024,025.47 in Q1 2021[47] - The cash inflow from financing activities in Q1 2022 was ¥7,247,400.00, a decrease from ¥25,672,750.00 in Q1 2021, showing a decline of approximately 71.7%[47] - The net increase in cash and cash equivalents for Q1 2022 was ¥228,605,661.83, compared to an increase of ¥7,519,488.08 in Q1 2021, indicating a substantial improvement[47] - The ending balance of cash and cash equivalents as of the end of Q1 2022 was ¥245,705,025.88, significantly higher than ¥75,837,833.33 at the end of Q1 2021[47] Assets and Liabilities - Total assets as of March 31, 2022, were CNY 679,354,800.06, a decrease of 1.19% compared to the end of 2021[16] - The asset-liability ratio for the consolidated entity was 20.04%, down from 21.90% at the end of 2021[16] - The total current assets decreased from 510,914,930.36 CNY on December 31, 2021, to 504,256,128.11 CNY on March 31, 2022[30] - The total liabilities decreased from 145,452,319.77 CNY on December 31, 2021, to 131,179,914.74 CNY on March 31, 2022[31] - The company's fixed assets are valued at 86,066,798.79 CNY as of March 31, 2022, down from 88,030,062.33 CNY at the end of 2021[31] - Total liabilities decreased to CNY 135,112,924.39 in Q1 2022 from CNY 149,145,017.47 in Q1 2021, reflecting a reduction of 9.4%[36] - Shareholders' equity increased to CNY 541,645,436.67 in Q1 2022 from CNY 534,641,447.45 in Q1 2021, representing a growth of 1.9%[36] Shareholder Information - The number of ordinary shareholders was 12,888 as of the report date[22] - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 85,738,590 shares, representing 59.02% of total shares[24] - The total shares held by the top ten shareholders amount to 98,258,941, which is 67.63% of the total shares[24] Operational Challenges - The company experienced a significant decline in sales due to reduced foot traffic in pharmacies and outpatient volumes in hospitals caused by the domestic pandemic[17] Research and Development - Research and development expenses increased to CNY 1,487,606.90 in Q1 2022, up 26.9% from CNY 1,171,860.85 in Q1 2021[40] Other Financial Metrics - The company's financial expenses rose significantly to CNY 800,522.41 in Q1 2022, compared to CNY 174,826.76 in Q1 2021[40] - Investment income for Q1 2022 was CNY 2,286,784.99, down 53.5% from CNY 4,913,126.27 in Q1 2021[40] - The company's sales expenses were CNY 11,928,031.13 in Q1 2022, slightly down from CNY 12,440,021.79 in Q1 2021[40] - The company's management expenses decreased to CNY 5,420,978.24 in Q1 2022 from CNY 5,618,307.52 in Q1 2021[40]